ResApp Health Limited announced that it has achieved Australian Therapeutics Good Administration (TGA) clearance and CE Mark certification for the regulatory-approved standalone cough counter smartphone application. The application is now listed on the Australian Register of Therapeutic Goods (ARTG) and available for sale in Europe as a class I medical device. ResApp's standalone cough counter application tracks cough frequency using only a smartphone. The application uses ResApp's proprietary machine learning algorithms to accurately identify cough events from audio recorded using the smartphone's in-built microphone. Cough frequency is a key factor in determining and managing respiratory disease progression and may also be a valuable outcome measure in clinical trials involving a broad range of disease states where cough is implicated. Traditionally, the only ways to measure the cough frequency is by subjective self-reporting or manually listening to audio recordings. These methods are labour intensive, not cost effective and inaccurate. The cough counting application was developed to deliver patients, healthcare providers and researchers more accurate and reliable analysis for disease monitoring. ResApp's cough counting technology is already being used by the global biopharmaceutical company AstraZeneca to monitor patients participating in a lung cancer clinical trial and an asthma management support program.